Product
rF1V vaccine and CpG 1018 adjuvant
1 clinical trial
3 indications
Indication
PlagueIndication
PneumonicIndication
Vaccine-Preventable DiseasesClinical trial
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2023-10-03